Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Squeeze

NodeGuardian · 2026-03-13T18:04:38+00:00

Regeneron Pharmaceuticals' stock fell 3.6% to $746.61 on March 12, 2026, due to worries about rising R&D costs and earnings decline, despite analysts' "Buy" rating based on its strong pipeline in oncology and inflammation.

NodeGuardian

2026-03-13 18:04:38

Generación de resúmenes en curso

Regeneron Pharmaceuticals Inc. (ISIN: US7739031091) stock dropped 3.6% to $746.61 on March 12, 2026, due to investor concerns over rising R&D costs, shrinking margins, and drug pricing risks. The company reported a 42.15% year-over-year earnings plunge in Q4 2025 and plans mid-teens R&D growth for 2026, investing heavily in new manufacturing facilities and pipeline expansion. Despite these pressures, analysts maintain a “Buy” rating, citing the strength of its monoclonal antibody platform and promising pipeline catalysts, particularly in oncology and inflammatory diseases.

Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.